- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
NOXXON Pharma Demonstrates Synergies between NOX-A12 and Therapies Working Through T Cells or NK Cells
NOXXON Pharma, a clinical-stage biopharmaceutical company primarily focused on cancer treatment, announced that it presented data yesterday at the ESMO conference in Copenhagen, Denmark, studying the role of CXCL12 inhibition by NOX-A12 (olaptesed pegol) in tumor stroma spheroids.
NOXXON Pharma N.V. (Paris:ALNOX) a clinical-stage biopharmaceutical company primarily focused on cancer treatment, announced that it presented data yesterday at the ESMO conference in Copenhagen, Denmark, studying the role of CXCL12 inhibition by NOX-A12 (olaptesed pegol) in tumor stroma spheroids, a preclinical model that mimics the complexity of the tumor microenvironment. These studies showed that NOX-A12 synergizes with therapies working through either T cells or NK cells. Further studies of NOX-A12 with agents working through T-cells such as checkpoint inhibitors or CAR-T cells as well as NK cell-based therapies are warranted.
Poster Title: CXCL12 Inhibition with NOX-A12 (Olaptesed Pegol)
Increases T and NK Cell Infiltration and Synergizes with Immune
Checkpoint Blockade and ADCC in Tumour-Stroma Spheroids
Authors:
Dirk Zboralski, Anna Kruschinski, Dirk Eulberg and Axel Vater
Location
& time: ESMO Congress 2016, Copenhagen, Denmark, 7-11 October
2016, Session Immunotherapy of cancer: Abstract #1083P, Hall E, Sunday,
9 October 2016, 13:00 – 14:00
The poster may be downloaded from the company’s website:
www.noxxon.com/downloads/poster/ESMO2016.pdf
NOX-A12, which inhibits the key tumor microenvironment chemokine CXCL12,
may be a key partner for a wide range of IO (immuno-oncology) agents.
NOXXON has generated promising pre-clinical and clinical data, including
recent animal data showing synergy with a checkpoint inhibitor as well
as recent phase 2a trials in multiple myeloma and a second hematological
cancer that showed a safety profile that supports further development
and first signs of efficacy. The company believes that additional
clinical trials are warranted to investigate combinations of NOX-A12
multiple classes of IO agents including those acting on or through
T-cells and NK cells.
About NOXXON
NOXXON Pharma N.V. is a clinical-stage
biopharmaceutical company focused on cancer treatment. NOXXON’s goal is
to significantly enhance the effectiveness of cancer treatments
including immuno-oncology approaches (such as immune checkpoint
inhibitors) and current standards of care (such as chemotherapy and
radiotherapy). NOXXON’s Spiegelmer® platform has
generated a proprietary pipeline of clinical-stage product candidates
including its lead cancer drug candidate NOX-A12. NOXXON is supported by
a strong group of leading international investors, including TVM
Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners,
DEWB, NGN and Seventure. NOXXON has its statutory seat in Amsterdam, The
Netherlands and its office in Berlin, Germany. Further information can
be found at: www.noxxon.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â